Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Diabetic Retinopathy | 78 | 2025 | 162 | 22.840 |
Why?
|
Angiogenesis Inhibitors | 103 | 2025 | 219 | 19.280 |
Why?
|
Macular Edema | 57 | 2025 | 92 | 15.760 |
Why?
|
Visual Acuity | 111 | 2025 | 705 | 14.690 |
Why?
|
Wet Macular Degeneration | 36 | 2025 | 44 | 10.810 |
Why?
|
Macular Degeneration | 33 | 2025 | 127 | 10.450 |
Why?
|
Ranibizumab | 61 | 2025 | 75 | 10.430 |
Why?
|
Vascular Endothelial Growth Factor A | 89 | 2025 | 446 | 10.000 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 51 | 2024 | 102 | 9.420 |
Why?
|
Intravitreal Injections | 101 | 2025 | 148 | 9.390 |
Why?
|
Tomography, Optical Coherence | 91 | 2025 | 561 | 8.830 |
Why?
|
Recombinant Fusion Proteins | 52 | 2025 | 801 | 8.670 |
Why?
|
Fluorescein Angiography | 69 | 2025 | 152 | 7.580 |
Why?
|
Geographic Atrophy | 17 | 2025 | 24 | 7.490 |
Why?
|
Macula Lutea | 19 | 2025 | 48 | 5.310 |
Why?
|
Retinal Diseases | 18 | 2024 | 180 | 4.880 |
Why?
|
Retinal Detachment | 16 | 2025 | 79 | 4.820 |
Why?
|
Diabetes Mellitus | 19 | 2024 | 930 | 4.660 |
Why?
|
Vitrectomy | 26 | 2025 | 91 | 4.640 |
Why?
|
Antibodies, Monoclonal, Humanized | 23 | 2024 | 551 | 4.390 |
Why?
|
Retinal Vein Occlusion | 17 | 2022 | 27 | 4.340 |
Why?
|
Retinal Vessels | 24 | 2024 | 78 | 4.330 |
Why?
|
Choroidal Neovascularization | 12 | 2023 | 34 | 4.220 |
Why?
|
Retinal Perforations | 10 | 2024 | 25 | 3.670 |
Why?
|
Laser Coagulation | 17 | 2023 | 128 | 3.530 |
Why?
|
Bevacizumab | 20 | 2024 | 79 | 2.910 |
Why?
|
Retina | 22 | 2023 | 499 | 2.510 |
Why?
|
Choroid | 9 | 2025 | 41 | 2.320 |
Why?
|
Humans | 250 | 2025 | 133390 | 2.170 |
Why?
|
Aged | 98 | 2025 | 21605 | 2.150 |
Why?
|
Scleral Buckling | 9 | 2022 | 14 | 2.120 |
Why?
|
Glucocorticoids | 10 | 2024 | 401 | 2.030 |
Why?
|
Endophthalmitis | 7 | 2016 | 69 | 2.020 |
Why?
|
Middle Aged | 105 | 2025 | 29208 | 2.020 |
Why?
|
Follow-Up Studies | 43 | 2025 | 5455 | 1.940 |
Why?
|
Aged, 80 and over | 49 | 2025 | 7159 | 1.790 |
Why?
|
Fundus Oculi | 21 | 2025 | 67 | 1.750 |
Why?
|
Prospective Studies | 48 | 2025 | 6570 | 1.700 |
Why?
|
Male | 124 | 2025 | 65685 | 1.630 |
Why?
|
Photography | 6 | 2022 | 88 | 1.620 |
Why?
|
Treatment Outcome | 58 | 2025 | 12971 | 1.610 |
Why?
|
Female | 129 | 2025 | 71455 | 1.570 |
Why?
|
Peptides, Cyclic | 2 | 2023 | 57 | 1.540 |
Why?
|
Ischemia | 10 | 2021 | 383 | 1.470 |
Why?
|
Retinal Pigment Epithelium | 6 | 2025 | 38 | 1.340 |
Why?
|
Retrospective Studies | 59 | 2025 | 17378 | 1.330 |
Why?
|
Vitreous Detachment | 3 | 2024 | 11 | 1.320 |
Why?
|
Complement Inactivating Agents | 4 | 2023 | 12 | 1.310 |
Why?
|
Complement C3 | 4 | 2023 | 54 | 1.250 |
Why?
|
Fovea Centralis | 4 | 2020 | 10 | 1.160 |
Why?
|
Endothelial Growth Factors | 12 | 2023 | 54 | 1.160 |
Why?
|
Eye Infections, Bacterial | 3 | 2016 | 86 | 1.150 |
Why?
|
Retinal Vasculitis | 4 | 2023 | 8 | 1.130 |
Why?
|
Triamcinolone Acetonide | 4 | 2024 | 36 | 1.110 |
Why?
|
Subretinal Fluid | 7 | 2024 | 11 | 1.060 |
Why?
|
Double-Blind Method | 16 | 2025 | 1654 | 1.060 |
Why?
|
Nerve Fibers | 3 | 2025 | 79 | 0.990 |
Why?
|
Retinal Telangiectasis | 3 | 2025 | 5 | 0.990 |
Why?
|
Epiretinal Membrane | 4 | 2024 | 14 | 0.960 |
Why?
|
Adult | 52 | 2025 | 31786 | 0.940 |
Why?
|
Peripherins | 1 | 2024 | 2 | 0.930 |
Why?
|
Disease Progression | 15 | 2025 | 2237 | 0.920 |
Why?
|
Fluocinolone Acetonide | 4 | 2020 | 6 | 0.880 |
Why?
|
Vitreous Body | 5 | 2024 | 101 | 0.850 |
Why?
|
Cataract | 3 | 2022 | 174 | 0.850 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2024 | 197 | 0.840 |
Why?
|
Cysts | 2 | 2024 | 104 | 0.840 |
Why?
|
Retinal Vein | 3 | 2022 | 11 | 0.820 |
Why?
|
Ophthalmology | 6 | 2024 | 198 | 0.800 |
Why?
|
Angiopoietin-2 | 4 | 2024 | 16 | 0.790 |
Why?
|
Drug Delivery Systems | 3 | 2025 | 232 | 0.790 |
Why?
|
Clinical Trials as Topic | 5 | 2023 | 1153 | 0.780 |
Why?
|
Benchmarking | 1 | 2023 | 146 | 0.780 |
Why?
|
Eye Infections, Fungal | 4 | 2014 | 73 | 0.770 |
Why?
|
Antibodies, Bispecific | 2 | 2024 | 51 | 0.760 |
Why?
|
Edema | 2 | 2022 | 140 | 0.730 |
Why?
|
Carbonic Anhydrases | 11 | 2003 | 26 | 0.720 |
Why?
|
Cataract Extraction | 3 | 2017 | 155 | 0.710 |
Why?
|
Neovascularization, Pathologic | 7 | 2018 | 263 | 0.700 |
Why?
|
Ophthalmoscopy | 3 | 2019 | 29 | 0.700 |
Why?
|
Ophthalmic Solutions | 2 | 2011 | 90 | 0.700 |
Why?
|
No-Show Patients | 1 | 2020 | 3 | 0.670 |
Why?
|
Basement Membrane | 5 | 2024 | 48 | 0.670 |
Why?
|
Vitreoretinal Surgery | 2 | 2021 | 6 | 0.670 |
Why?
|
Vision Disorders | 4 | 2023 | 221 | 0.670 |
Why?
|
Lost to Follow-Up | 1 | 2020 | 33 | 0.660 |
Why?
|
Retinal Hemorrhage | 2 | 2017 | 26 | 0.650 |
Why?
|
Sensory Thresholds | 1 | 2019 | 38 | 0.640 |
Why?
|
Patient Dropouts | 1 | 2019 | 52 | 0.640 |
Why?
|
Anti-Inflammatory Agents | 2 | 2019 | 315 | 0.630 |
Why?
|
Postoperative Complications | 4 | 2017 | 3155 | 0.630 |
Why?
|
Time Factors | 12 | 2025 | 6569 | 0.610 |
Why?
|
Choroid Diseases | 1 | 2019 | 23 | 0.610 |
Why?
|
Eye Diseases | 2 | 2011 | 130 | 0.590 |
Why?
|
Microaneurysm | 3 | 2023 | 3 | 0.570 |
Why?
|
Monitoring, Physiologic | 1 | 2020 | 388 | 0.570 |
Why?
|
Retinal Degeneration | 3 | 2025 | 104 | 0.550 |
Why?
|
Lasers | 2 | 2017 | 115 | 0.530 |
Why?
|
Patient Compliance | 1 | 2019 | 477 | 0.510 |
Why?
|
Drug Administration Schedule | 6 | 2022 | 755 | 0.510 |
Why?
|
Lasers, Solid-State | 1 | 2016 | 17 | 0.500 |
Why?
|
Biomarkers | 11 | 2025 | 3424 | 0.500 |
Why?
|
Meningoencephalitis | 1 | 2016 | 22 | 0.490 |
Why?
|
Retinitis | 1 | 2016 | 18 | 0.490 |
Why?
|
Anti-Bacterial Agents | 5 | 2019 | 2509 | 0.470 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2024 | 1210 | 0.470 |
Why?
|
Antibiotic Prophylaxis | 1 | 2016 | 126 | 0.470 |
Why?
|
Silicone Oils | 2 | 2025 | 8 | 0.470 |
Why?
|
Atrophy | 7 | 2025 | 251 | 0.460 |
Why?
|
Vancomycin | 1 | 2017 | 235 | 0.450 |
Why?
|
Waldenstrom Macroglobulinemia | 1 | 2018 | 154 | 0.450 |
Why?
|
Cell Hypoxia | 12 | 2004 | 104 | 0.450 |
Why?
|
Povidone-Iodine | 2 | 2011 | 10 | 0.450 |
Why?
|
Clinical Protocols | 5 | 2022 | 245 | 0.450 |
Why?
|
Mutation | 3 | 2025 | 6290 | 0.450 |
Why?
|
Injections, Intraocular | 3 | 2024 | 10 | 0.440 |
Why?
|
West Nile Fever | 1 | 2016 | 139 | 0.430 |
Why?
|
Central Serous Chorioretinopathy | 2 | 2025 | 8 | 0.430 |
Why?
|
Cryosurgery | 1 | 2013 | 48 | 0.420 |
Why?
|
Fungi | 3 | 2014 | 75 | 0.410 |
Why?
|
Carcinoma, Renal Cell | 4 | 2004 | 253 | 0.410 |
Why?
|
Precision Medicine | 2 | 2018 | 355 | 0.410 |
Why?
|
Retinal Ganglion Cells | 2 | 2025 | 120 | 0.410 |
Why?
|
Uveitis | 2 | 2024 | 38 | 0.400 |
Why?
|
Choroid Neoplasms | 2 | 2013 | 25 | 0.390 |
Why?
|
Vitreoretinopathy, Proliferative | 2 | 2022 | 7 | 0.380 |
Why?
|
Transcription Factors | 10 | 2004 | 2704 | 0.380 |
Why?
|
Nuclear Proteins | 9 | 2004 | 1334 | 0.380 |
Why?
|
Antisepsis | 1 | 2011 | 7 | 0.380 |
Why?
|
Mycoses | 2 | 2014 | 119 | 0.370 |
Why?
|
Ophthalmologists | 2 | 2024 | 14 | 0.370 |
Why?
|
Ciliary Body | 1 | 2011 | 28 | 0.360 |
Why?
|
Bacteria | 2 | 2016 | 533 | 0.360 |
Why?
|
Eye | 2 | 2024 | 245 | 0.360 |
Why?
|
Young Adult | 9 | 2025 | 9852 | 0.360 |
Why?
|
Retinal Neovascularization | 3 | 2020 | 17 | 0.360 |
Why?
|
Surgical Wound Infection | 2 | 2017 | 273 | 0.350 |
Why?
|
Endotamponade | 3 | 2025 | 7 | 0.350 |
Why?
|
Ubiquitin-Protein Ligases | 3 | 2004 | 388 | 0.350 |
Why?
|
Kidney Neoplasms | 4 | 2004 | 461 | 0.350 |
Why?
|
Tumor Suppressor Proteins | 3 | 2004 | 509 | 0.350 |
Why?
|
Retinitis Pigmentosa | 2 | 2025 | 95 | 0.350 |
Why?
|
Uveal Neoplasms | 1 | 2011 | 60 | 0.340 |
Why?
|
Retreatment | 4 | 2018 | 92 | 0.340 |
Why?
|
Algorithms | 6 | 2024 | 1729 | 0.340 |
Why?
|
Retinal Drusen | 3 | 2024 | 6 | 0.340 |
Why?
|
Regression Analysis | 3 | 2022 | 825 | 0.340 |
Why?
|
Aging | 1 | 2018 | 1297 | 0.340 |
Why?
|
Surgical Flaps | 2 | 2024 | 196 | 0.340 |
Why?
|
Diagnosis, Differential | 3 | 2024 | 1968 | 0.340 |
Why?
|
Hospitals, University | 1 | 2010 | 105 | 0.330 |
Why?
|
Antibodies, Monoclonal | 3 | 2019 | 1068 | 0.330 |
Why?
|
Cephalosporins | 1 | 2011 | 143 | 0.330 |
Why?
|
Neoplasm Proteins | 10 | 2004 | 716 | 0.330 |
Why?
|
Regional Blood Flow | 3 | 2019 | 226 | 0.320 |
Why?
|
Drug Hypersensitivity | 1 | 2011 | 100 | 0.320 |
Why?
|
Pharmaceutical Preparations | 3 | 2023 | 91 | 0.310 |
Why?
|
Monitoring, Intraoperative | 1 | 2010 | 134 | 0.310 |
Why?
|
Cryptococcosis | 1 | 2009 | 44 | 0.310 |
Why?
|
Quality of Life | 4 | 2023 | 2137 | 0.310 |
Why?
|
Oculomotor Nerve | 1 | 2008 | 7 | 0.300 |
Why?
|
DNA-Binding Proteins | 8 | 2004 | 2161 | 0.300 |
Why?
|
Cranial Nerve Neoplasms | 1 | 2008 | 8 | 0.300 |
Why?
|
Capillary Permeability | 2 | 2020 | 77 | 0.300 |
Why?
|
Drug Therapy, Combination | 4 | 2025 | 1193 | 0.300 |
Why?
|
Oculomotor Nerve Diseases | 1 | 2008 | 18 | 0.300 |
Why?
|
Eye Injuries, Penetrating | 1 | 2008 | 17 | 0.290 |
Why?
|
Blindness | 2 | 2021 | 76 | 0.290 |
Why?
|
Risk Factors | 11 | 2024 | 11085 | 0.290 |
Why?
|
Exudates and Transudates | 2 | 2021 | 22 | 0.290 |
Why?
|
Rhabdoid Tumor | 1 | 2008 | 56 | 0.290 |
Why?
|
Adolescent | 7 | 2024 | 20505 | 0.290 |
Why?
|
Antigens, Neoplasm | 8 | 2003 | 407 | 0.280 |
Why?
|
Corneal Ulcer | 1 | 2008 | 55 | 0.280 |
Why?
|
Combined Modality Therapy | 8 | 2020 | 1306 | 0.280 |
Why?
|
Vitelliform Macular Dystrophy | 2 | 2024 | 2 | 0.280 |
Why?
|
Single-Blind Method | 2 | 2021 | 248 | 0.270 |
Why?
|
Teratoma | 1 | 2008 | 130 | 0.270 |
Why?
|
Cross Infection | 1 | 2010 | 332 | 0.270 |
Why?
|
Practice Guidelines as Topic | 3 | 2024 | 1334 | 0.260 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2002 | 2120 | 0.250 |
Why?
|
Keratomileusis, Laser In Situ | 1 | 2006 | 97 | 0.240 |
Why?
|
Severity of Illness Index | 5 | 2021 | 3082 | 0.240 |
Why?
|
Hexokinase | 1 | 2025 | 24 | 0.240 |
Why?
|
Myopia | 1 | 2006 | 132 | 0.230 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 3733 | 0.230 |
Why?
|
Gene Expression Profiling | 2 | 2004 | 1918 | 0.230 |
Why?
|
United States | 9 | 2024 | 11677 | 0.230 |
Why?
|
Biomarkers, Tumor | 7 | 2008 | 1717 | 0.230 |
Why?
|
Melanoma | 2 | 2013 | 964 | 0.230 |
Why?
|
Intraocular Pressure | 2 | 2024 | 136 | 0.230 |
Why?
|
Aqueous Humor | 2 | 2022 | 28 | 0.220 |
Why?
|
Oxygen | 6 | 2018 | 577 | 0.220 |
Why?
|
Angiopoietins | 2 | 2021 | 21 | 0.220 |
Why?
|
Drug Approval | 1 | 2024 | 45 | 0.220 |
Why?
|
Complement C5 | 1 | 2023 | 7 | 0.220 |
Why?
|
Cross-Over Studies | 1 | 2025 | 328 | 0.220 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 2 | 2002 | 74 | 0.210 |
Why?
|
Ligases | 2 | 2000 | 48 | 0.210 |
Why?
|
Cyclin D1 | 1 | 2004 | 123 | 0.210 |
Why?
|
Tumor Cells, Cultured | 9 | 2004 | 1102 | 0.210 |
Why?
|
Hypoxia | 4 | 2004 | 263 | 0.210 |
Why?
|
Entropy | 1 | 2023 | 29 | 0.210 |
Why?
|
United States Food and Drug Administration | 1 | 2024 | 158 | 0.210 |
Why?
|
Meta-Analysis as Topic | 1 | 2024 | 173 | 0.210 |
Why?
|
Photochemotherapy | 2 | 2022 | 44 | 0.210 |
Why?
|
Biosimilar Pharmaceuticals | 1 | 2023 | 6 | 0.210 |
Why?
|
Aptamers, Nucleotide | 1 | 2023 | 35 | 0.210 |
Why?
|
Drainage | 1 | 2025 | 264 | 0.210 |
Why?
|
Evidence-Based Medicine | 2 | 2024 | 677 | 0.210 |
Why?
|
Traction | 1 | 2022 | 9 | 0.200 |
Why?
|
Hypoxia-Inducible Factor 1, alpha Subunit | 9 | 2004 | 104 | 0.200 |
Why?
|
Drug Resistance | 2 | 2013 | 264 | 0.200 |
Why?
|
Eye Neoplasms | 2 | 2013 | 53 | 0.190 |
Why?
|
Prone Position | 1 | 2022 | 33 | 0.190 |
Why?
|
Hypoxia-Inducible Factor 1 | 8 | 2004 | 19 | 0.190 |
Why?
|
Porphyrins | 1 | 2022 | 18 | 0.190 |
Why?
|
Delphi Technique | 1 | 2023 | 243 | 0.190 |
Why?
|
Polyethylene Glycols | 1 | 2023 | 252 | 0.190 |
Why?
|
Imaging, Three-Dimensional | 1 | 2024 | 394 | 0.190 |
Why?
|
Biomedical Research | 2 | 2019 | 555 | 0.180 |
Why?
|
Equipment Design | 2 | 2020 | 604 | 0.180 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 4 | 2012 | 377 | 0.180 |
Why?
|
Cornea | 1 | 2006 | 594 | 0.180 |
Why?
|
Postoperative Period | 2 | 2020 | 341 | 0.180 |
Why?
|
Confidence Intervals | 1 | 2021 | 300 | 0.180 |
Why?
|
Blood-Retinal Barrier | 2 | 2020 | 3 | 0.180 |
Why?
|
Drug Implants | 2 | 2020 | 43 | 0.180 |
Why?
|
Computer Systems | 1 | 2021 | 38 | 0.180 |
Why?
|
Dose-Response Relationship, Drug | 4 | 2020 | 1733 | 0.170 |
Why?
|
Registries | 3 | 2023 | 1568 | 0.170 |
Why?
|
Videoconferencing | 1 | 2020 | 22 | 0.170 |
Why?
|
Cytokines | 3 | 2022 | 1393 | 0.170 |
Why?
|
Surgery, Computer-Assisted | 2 | 2020 | 64 | 0.170 |
Why?
|
Patient Reported Outcome Measures | 1 | 2022 | 204 | 0.160 |
Why?
|
Fractals | 1 | 2019 | 2 | 0.160 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2019 | 20 | 0.160 |
Why?
|
Consensus | 1 | 2023 | 737 | 0.160 |
Why?
|
Microcirculation | 2 | 2019 | 116 | 0.160 |
Why?
|
Income | 1 | 2020 | 140 | 0.160 |
Why?
|
Recurrence | 3 | 2019 | 1464 | 0.160 |
Why?
|
Congresses as Topic | 1 | 2020 | 187 | 0.160 |
Why?
|
Biological Products | 1 | 2021 | 137 | 0.150 |
Why?
|
Insurance Coverage | 1 | 2020 | 124 | 0.150 |
Why?
|
Early Diagnosis | 1 | 2019 | 197 | 0.150 |
Why?
|
Longitudinal Studies | 2 | 2022 | 1493 | 0.150 |
Why?
|
Antifungal Agents | 3 | 2014 | 306 | 0.150 |
Why?
|
Delayed-Action Preparations | 1 | 2018 | 125 | 0.150 |
Why?
|
Cost-Benefit Analysis | 1 | 2021 | 561 | 0.150 |
Why?
|
Continuity of Patient Care | 1 | 2020 | 153 | 0.150 |
Why?
|
Diagnostic Techniques, Ophthalmological | 1 | 2019 | 86 | 0.140 |
Why?
|
Necrosis | 7 | 2004 | 221 | 0.140 |
Why?
|
Vision, Low | 1 | 2017 | 15 | 0.140 |
Why?
|
Visual Prosthesis | 1 | 2017 | 6 | 0.140 |
Why?
|
Proteins | 2 | 2000 | 1087 | 0.140 |
Why?
|
Ultrasonography | 3 | 2024 | 997 | 0.140 |
Why?
|
Breast Neoplasms | 5 | 2004 | 2762 | 0.140 |
Why?
|
Betacoronavirus | 1 | 2020 | 304 | 0.130 |
Why?
|
Drug and Narcotic Control | 1 | 2016 | 16 | 0.130 |
Why?
|
Legislation, Drug | 1 | 2016 | 9 | 0.130 |
Why?
|
Prosthesis Implantation | 1 | 2017 | 143 | 0.130 |
Why?
|
Beryllium | 1 | 2016 | 3 | 0.130 |
Why?
|
Administration, Topical | 1 | 2016 | 142 | 0.130 |
Why?
|
Cohort Studies | 6 | 2022 | 5175 | 0.120 |
Why?
|
Genes, Tumor Suppressor | 3 | 2002 | 225 | 0.120 |
Why?
|
Therapeutic Equivalency | 1 | 2015 | 13 | 0.120 |
Why?
|
Patient Acceptance of Health Care | 1 | 2020 | 471 | 0.120 |
Why?
|
Photoreceptor Cells, Vertebrate | 1 | 2015 | 41 | 0.120 |
Why?
|
Coronavirus Infections | 1 | 2020 | 383 | 0.120 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 394 | 0.120 |
Why?
|
Lung Neoplasms | 4 | 2012 | 1787 | 0.110 |
Why?
|
Medication Adherence | 1 | 2018 | 338 | 0.110 |
Why?
|
Vascular Endothelial Growth Factors | 3 | 2023 | 53 | 0.110 |
Why?
|
Von Hippel-Lindau Tumor Suppressor Protein | 3 | 2004 | 37 | 0.110 |
Why?
|
Fluconazole | 2 | 2014 | 50 | 0.110 |
Why?
|
Amphotericin B | 2 | 2014 | 91 | 0.100 |
Why?
|
von Hippel-Lindau Disease | 3 | 2002 | 20 | 0.100 |
Why?
|
History, 18th Century | 1 | 2013 | 70 | 0.100 |
Why?
|
Practice Patterns, Physicians' | 1 | 2019 | 765 | 0.100 |
Why?
|
Electronic Health Records | 1 | 2020 | 792 | 0.100 |
Why?
|
Carbonic Anhydrase IX | 8 | 2003 | 13 | 0.100 |
Why?
|
Observational Studies as Topic | 2 | 2023 | 103 | 0.100 |
Why?
|
Anterior Chamber | 1 | 2012 | 33 | 0.090 |
Why?
|
Electroretinography | 2 | 2025 | 123 | 0.090 |
Why?
|
Blood Glucose | 1 | 2016 | 1189 | 0.090 |
Why?
|
Chlorhexidine | 1 | 2011 | 47 | 0.090 |
Why?
|
Telemedicine | 1 | 2018 | 500 | 0.090 |
Why?
|
Lymphokines | 2 | 2002 | 69 | 0.090 |
Why?
|
Refraction, Ocular | 1 | 2013 | 217 | 0.090 |
Why?
|
Drug Costs | 1 | 2011 | 66 | 0.090 |
Why?
|
Liver Function Tests | 1 | 2011 | 107 | 0.090 |
Why?
|
Retinopathy of Prematurity | 1 | 2011 | 64 | 0.090 |
Why?
|
Age Factors | 1 | 2018 | 2984 | 0.090 |
Why?
|
Laser Therapy | 1 | 2013 | 227 | 0.090 |
Why?
|
Glucose | 1 | 2015 | 923 | 0.090 |
Why?
|
Florida | 1 | 2010 | 79 | 0.080 |
Why?
|
Decision Making | 1 | 2015 | 698 | 0.080 |
Why?
|
Acute Disease | 2 | 2010 | 1190 | 0.080 |
Why?
|
Penicillins | 1 | 2011 | 155 | 0.080 |
Why?
|
Prognosis | 7 | 2024 | 5074 | 0.080 |
Why?
|
Signal Transduction | 3 | 2021 | 4897 | 0.080 |
Why?
|
Neoplasms | 2 | 2004 | 3024 | 0.080 |
Why?
|
Child | 3 | 2024 | 25733 | 0.080 |
Why?
|
Flucytosine | 1 | 2009 | 17 | 0.080 |
Why?
|
Cryptococcus neoformans | 1 | 2009 | 23 | 0.080 |
Why?
|
Immunohistochemistry | 6 | 2003 | 1760 | 0.080 |
Why?
|
Clinical Trials, Phase III as Topic | 2 | 2021 | 76 | 0.080 |
Why?
|
Intraoperative Complications | 1 | 2010 | 162 | 0.080 |
Why?
|
In Situ Hybridization | 4 | 2004 | 484 | 0.080 |
Why?
|
Meningeal Carcinomatosis | 1 | 2008 | 5 | 0.080 |
Why?
|
Preoperative Care | 1 | 2011 | 368 | 0.080 |
Why?
|
Subarachnoid Space | 1 | 2008 | 25 | 0.080 |
Why?
|
Diagnostic Imaging | 1 | 2011 | 317 | 0.080 |
Why?
|
Mesencephalon | 1 | 2008 | 38 | 0.070 |
Why?
|
Neoplasm Invasiveness | 2 | 2008 | 667 | 0.070 |
Why?
|
Eye Enucleation | 1 | 2008 | 50 | 0.070 |
Why?
|
Incidence | 1 | 2016 | 3396 | 0.070 |
Why?
|
Keratoplasty, Penetrating | 1 | 2008 | 51 | 0.070 |
Why?
|
Reproducibility of Results | 3 | 2020 | 3025 | 0.070 |
Why?
|
Fatal Outcome | 1 | 2008 | 376 | 0.070 |
Why?
|
Treatment Failure | 1 | 2008 | 364 | 0.070 |
Why?
|
Blotting, Western | 4 | 2003 | 1134 | 0.070 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2001 | 872 | 0.070 |
Why?
|
Case-Control Studies | 2 | 2024 | 3642 | 0.070 |
Why?
|
Urinary Bladder Neoplasms | 2 | 2002 | 557 | 0.060 |
Why?
|
Body Weights and Measures | 1 | 2006 | 41 | 0.060 |
Why?
|
Capillaries | 2 | 2017 | 70 | 0.060 |
Why?
|
Neurosurgical Procedures | 1 | 2008 | 317 | 0.060 |
Why?
|
Head and Neck Neoplasms | 2 | 2001 | 699 | 0.060 |
Why?
|
Hydrocephalus | 1 | 2008 | 275 | 0.060 |
Why?
|
Pilot Projects | 2 | 2020 | 1481 | 0.060 |
Why?
|
Transfection | 3 | 2004 | 1089 | 0.060 |
Why?
|
Phenotype | 3 | 2025 | 4551 | 0.060 |
Why?
|
Magnetic Resonance Imaging | 2 | 2024 | 3839 | 0.060 |
Why?
|
Basic Helix-Loop-Helix Transcription Factors | 3 | 2003 | 406 | 0.060 |
Why?
|
Immunoblotting | 2 | 2004 | 317 | 0.060 |
Why?
|
Suspensions | 1 | 2024 | 10 | 0.060 |
Why?
|
Search Engine | 1 | 2023 | 10 | 0.050 |
Why?
|
Pandemics | 2 | 2023 | 1189 | 0.050 |
Why?
|
Organic Chemicals | 1 | 2023 | 60 | 0.050 |
Why?
|
Plasmids | 2 | 2004 | 526 | 0.050 |
Why?
|
RNA, Messenger | 4 | 2004 | 2899 | 0.050 |
Why?
|
Vitreous Hemorrhage | 1 | 2023 | 9 | 0.050 |
Why?
|
Equivalence Trials as Topic | 1 | 2023 | 14 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor C | 1 | 2023 | 10 | 0.050 |
Why?
|
Inflammation | 2 | 2022 | 1590 | 0.050 |
Why?
|
DNA Mutational Analysis | 1 | 2025 | 838 | 0.050 |
Why?
|
Nephrons | 1 | 2002 | 21 | 0.050 |
Why?
|
Neurofibromin 2 | 1 | 2022 | 11 | 0.050 |
Why?
|
Indocyanine Green | 2 | 2015 | 62 | 0.050 |
Why?
|
Adenocarcinoma, Clear Cell | 1 | 2002 | 25 | 0.050 |
Why?
|
Syringes | 1 | 2022 | 25 | 0.050 |
Why?
|
Cell Division | 2 | 2001 | 773 | 0.050 |
Why?
|
Photosensitizing Agents | 1 | 2022 | 38 | 0.050 |
Why?
|
Up-Regulation | 2 | 2004 | 905 | 0.050 |
Why?
|
Data Interpretation, Statistical | 1 | 2023 | 239 | 0.050 |
Why?
|
Pentosan Sulfuric Polyester | 1 | 2021 | 1 | 0.050 |
Why?
|
Cell Adhesion Molecule-1 | 1 | 2021 | 1 | 0.050 |
Why?
|
Monocyte Chemoattractant Proteins | 1 | 2021 | 9 | 0.050 |
Why?
|
Canada | 1 | 2022 | 343 | 0.050 |
Why?
|
Neoplasm Recurrence, Local | 1 | 2008 | 1313 | 0.050 |
Why?
|
Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2021 | 29 | 0.050 |
Why?
|
Urokinase-Type Plasminogen Activator | 1 | 2021 | 39 | 0.050 |
Why?
|
Tissue Inhibitor of Metalloproteinase-1 | 1 | 2021 | 40 | 0.050 |
Why?
|
Sensitivity and Specificity | 2 | 2019 | 2160 | 0.040 |
Why?
|
Pedigree | 1 | 2025 | 1694 | 0.040 |
Why?
|
Genetic Association Studies | 1 | 2025 | 844 | 0.040 |
Why?
|
RNA | 2 | 2004 | 600 | 0.040 |
Why?
|
Helix-Loop-Helix Motifs | 1 | 2001 | 43 | 0.040 |
Why?
|
Ribonucleases | 1 | 2000 | 51 | 0.040 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2002 | 1070 | 0.040 |
Why?
|
Iatrogenic Disease | 1 | 2021 | 132 | 0.040 |
Why?
|
Radiation-Sensitizing Agents | 1 | 2000 | 28 | 0.040 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 1 | 2008 | 1349 | 0.040 |
Why?
|
Extracellular Space | 1 | 2001 | 89 | 0.040 |
Why?
|
Antigens, Nuclear | 1 | 2001 | 57 | 0.040 |
Why?
|
Carcinoma, Ductal, Breast | 1 | 2001 | 91 | 0.040 |
Why?
|
Organ Size | 1 | 2022 | 466 | 0.040 |
Why?
|
Multicenter Studies as Topic | 1 | 2021 | 289 | 0.040 |
Why?
|
Machine Learning | 1 | 2024 | 334 | 0.040 |
Why?
|
Slit Lamp Microscopy | 1 | 2020 | 6 | 0.040 |
Why?
|
Antibody Specificity | 1 | 2001 | 206 | 0.040 |
Why?
|
Saccharomyces cerevisiae Proteins | 1 | 2002 | 283 | 0.040 |
Why?
|
Nitroimidazoles | 1 | 2000 | 44 | 0.040 |
Why?
|
Liver Neoplasms | 1 | 2011 | 1411 | 0.040 |
Why?
|
Half-Life | 1 | 2020 | 160 | 0.040 |
Why?
|
Observation | 1 | 2020 | 45 | 0.040 |
Why?
|
Erythropoietin | 1 | 2001 | 110 | 0.040 |
Why?
|
Trans-Activators | 2 | 2001 | 830 | 0.040 |
Why?
|
Homeodomain Proteins | 1 | 2003 | 584 | 0.040 |
Why?
|
Immunoglobulin Fab Fragments | 1 | 2019 | 65 | 0.040 |
Why?
|
Protein Isoforms | 1 | 2001 | 429 | 0.040 |
Why?
|
Genes, Reporter | 1 | 2000 | 394 | 0.040 |
Why?
|
Breast | 1 | 2001 | 218 | 0.040 |
Why?
|
Calcinosis | 1 | 2001 | 193 | 0.040 |
Why?
|
Repressor Proteins | 1 | 2004 | 869 | 0.040 |
Why?
|
Promoter Regions, Genetic | 2 | 2000 | 1417 | 0.040 |
Why?
|
Medicare | 1 | 2023 | 463 | 0.040 |
Why?
|
Genetic Therapy | 1 | 2024 | 733 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2021 | 449 | 0.040 |
Why?
|
Protein Binding | 2 | 2020 | 1832 | 0.040 |
Why?
|
Cells | 1 | 1999 | 25 | 0.040 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2020 | 234 | 0.040 |
Why?
|
Genotype | 1 | 2025 | 2804 | 0.040 |
Why?
|
Gene Expression Regulation | 4 | 2004 | 2651 | 0.040 |
Why?
|
Research Design | 1 | 2023 | 746 | 0.040 |
Why?
|
Specialization | 1 | 2019 | 82 | 0.040 |
Why?
|
Cell Cycle Proteins | 1 | 2002 | 697 | 0.040 |
Why?
|
Expert Testimony | 1 | 2018 | 37 | 0.040 |
Why?
|
Quality Improvement | 1 | 2024 | 691 | 0.040 |
Why?
|
Anesthetics, Local | 1 | 2019 | 91 | 0.040 |
Why?
|
Health Care Surveys | 1 | 2019 | 293 | 0.040 |
Why?
|
Hemorrhage | 1 | 2021 | 508 | 0.040 |
Why?
|
Carcinoma | 1 | 2000 | 322 | 0.040 |
Why?
|
Caveolins | 1 | 1997 | 15 | 0.030 |
Why?
|
Models, Genetic | 1 | 2000 | 789 | 0.030 |
Why?
|
Multimodal Imaging | 1 | 2018 | 112 | 0.030 |
Why?
|
European Union | 1 | 2016 | 13 | 0.030 |
Why?
|
Infant | 2 | 2011 | 13158 | 0.030 |
Why?
|
Emergency Medical Services | 1 | 2021 | 414 | 0.030 |
Why?
|
Anticoagulants | 1 | 2021 | 599 | 0.030 |
Why?
|
Tomography, X-Ray Computed | 1 | 2024 | 2171 | 0.030 |
Why?
|
Gene Expression | 1 | 2001 | 1614 | 0.030 |
Why?
|
Internet | 1 | 2019 | 403 | 0.030 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2018 | 866 | 0.030 |
Why?
|
Delivery of Health Care | 1 | 2022 | 676 | 0.030 |
Why?
|
Drug Substitution | 1 | 2015 | 20 | 0.030 |
Why?
|
Voriconazole | 1 | 2014 | 34 | 0.030 |
Why?
|
Prosthesis Design | 1 | 2017 | 658 | 0.030 |
Why?
|
COS Cells | 2 | 2004 | 283 | 0.030 |
Why?
|
Survival Analysis | 3 | 2003 | 1596 | 0.030 |
Why?
|
Logistic Models | 1 | 2019 | 1907 | 0.030 |
Why?
|
Cell Transformation, Neoplastic | 1 | 1997 | 644 | 0.030 |
Why?
|
Recombinant Proteins | 1 | 1997 | 1437 | 0.030 |
Why?
|
Observer Variation | 1 | 2014 | 312 | 0.030 |
Why?
|
Drug-Related Side Effects and Adverse Reactions | 1 | 2016 | 282 | 0.030 |
Why?
|
Light Coagulation | 1 | 2013 | 24 | 0.030 |
Why?
|
RNA, Neoplasm | 2 | 2004 | 144 | 0.030 |
Why?
|
Visual Fields | 1 | 2014 | 147 | 0.030 |
Why?
|
Nevus | 1 | 2013 | 35 | 0.030 |
Why?
|
Skin Neoplasms | 1 | 2000 | 903 | 0.030 |
Why?
|
Hyperthermia, Induced | 1 | 2013 | 59 | 0.030 |
Why?
|
Immunoenzyme Techniques | 2 | 2002 | 258 | 0.020 |
Why?
|
Hemangioma | 1 | 2013 | 97 | 0.020 |
Why?
|
Retinoblastoma | 1 | 2013 | 117 | 0.020 |
Why?
|
Child, Preschool | 2 | 2022 | 14788 | 0.020 |
Why?
|
Mass Screening | 1 | 2018 | 834 | 0.020 |
Why?
|
Retinal Neoplasms | 1 | 2013 | 103 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2014 | 397 | 0.020 |
Why?
|
Radiation Injuries | 1 | 2013 | 165 | 0.020 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 72 | 0.020 |
Why?
|
Enzyme Induction | 2 | 2001 | 104 | 0.020 |
Why?
|
Microbial Sensitivity Tests | 1 | 2014 | 826 | 0.020 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 2019 | 867 | 0.020 |
Why?
|
Prevalence | 1 | 2016 | 2651 | 0.020 |
Why?
|
Coloring Agents | 1 | 2009 | 78 | 0.020 |
Why?
|
Fluorescence | 1 | 2009 | 103 | 0.020 |
Why?
|
Membrane Proteins | 1 | 1997 | 1603 | 0.020 |
Why?
|
Response Elements | 2 | 1999 | 106 | 0.020 |
Why?
|
Diabetes Mellitus, Type 2 | 1 | 2019 | 1405 | 0.020 |
Why?
|
Syndrome | 1 | 2009 | 1158 | 0.020 |
Why?
|
Hypoxia-Inducible Factor-Proline Dioxygenases | 1 | 2004 | 22 | 0.010 |
Why?
|
Procollagen-Proline Dioxygenase | 1 | 2004 | 36 | 0.010 |
Why?
|
Immune Sera | 1 | 2004 | 95 | 0.010 |
Why?
|
Mixed Function Oxygenases | 1 | 2004 | 35 | 0.010 |
Why?
|
Immediate-Early Proteins | 1 | 2004 | 60 | 0.010 |
Why?
|
Tissue Distribution | 1 | 2004 | 400 | 0.010 |
Why?
|
Doxycycline | 1 | 2004 | 121 | 0.010 |
Why?
|
Survival | 1 | 2003 | 19 | 0.010 |
Why?
|
Microscopy, Fluorescence | 1 | 2004 | 336 | 0.010 |
Why?
|
Animals | 5 | 2004 | 36377 | 0.010 |
Why?
|
Apoptosis | 2 | 2002 | 1928 | 0.010 |
Why?
|
Receptors, Antigen, B-Cell | 1 | 2002 | 33 | 0.010 |
Why?
|
Glucose Transporter Type 1 | 1 | 2002 | 26 | 0.010 |
Why?
|
RNA Probes | 1 | 2002 | 31 | 0.010 |
Why?
|
RNA Interference | 1 | 2004 | 543 | 0.010 |
Why?
|
Isoenzymes | 1 | 2003 | 231 | 0.010 |
Why?
|
Monosaccharide Transport Proteins | 1 | 2002 | 43 | 0.010 |
Why?
|
In Situ Nick-End Labeling | 1 | 2002 | 128 | 0.010 |
Why?
|
RNA, Small Interfering | 1 | 2004 | 714 | 0.010 |
Why?
|
Down-Regulation | 1 | 2004 | 717 | 0.010 |
Why?
|
Thymidine Phosphorylase | 1 | 2001 | 13 | 0.010 |
Why?
|
Mice, Inbred BALB C | 1 | 2004 | 1079 | 0.010 |
Why?
|
Mucin-1 | 1 | 2001 | 37 | 0.010 |
Why?
|
Fibroblast Growth Factor 2 | 1 | 2001 | 53 | 0.010 |
Why?
|
DNA Primers | 1 | 2002 | 669 | 0.010 |
Why?
|
England | 1 | 2001 | 72 | 0.010 |
Why?
|
Drug Therapy | 1 | 2001 | 93 | 0.010 |
Why?
|
Protein Kinases | 1 | 2002 | 343 | 0.010 |
Why?
|
Nephrectomy | 1 | 2002 | 180 | 0.010 |
Why?
|
Radiotherapy | 1 | 2001 | 148 | 0.010 |
Why?
|
Endothelium, Vascular | 1 | 2003 | 522 | 0.010 |
Why?
|
Antigens, CD | 1 | 2002 | 452 | 0.010 |
Why?
|
ErbB Receptors | 1 | 2001 | 302 | 0.010 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2002 | 1326 | 0.010 |
Why?
|
Mice | 3 | 2004 | 18910 | 0.010 |
Why?
|
Cobalt | 1 | 1999 | 18 | 0.010 |
Why?
|
Iron Chelating Agents | 1 | 1999 | 15 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2003 | 1488 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2001 | 971 | 0.010 |
Why?
|
Cell Line | 1 | 2004 | 2836 | 0.010 |
Why?
|
Multienzyme Complexes | 1 | 1999 | 88 | 0.010 |
Why?
|
Adaptor Proteins, Signal Transducing | 1 | 2002 | 619 | 0.010 |
Why?
|
Transcription, Genetic | 1 | 2004 | 1755 | 0.010 |
Why?
|
Cysteine Endopeptidases | 1 | 1999 | 119 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2011 | 8586 | 0.010 |
Why?
|
Proteasome Endopeptidase Complex | 1 | 1999 | 271 | 0.010 |
Why?
|
Receptor, ErbB-2 | 1 | 2001 | 559 | 0.010 |
Why?
|
Survival Rate | 1 | 2003 | 2210 | 0.010 |
Why?
|
Genes, fos | 1 | 1997 | 15 | 0.010 |
Why?
|
Mammals | 1 | 1999 | 277 | 0.010 |
Why?
|
3T3 Cells | 1 | 1997 | 122 | 0.010 |
Why?
|
Caveolin 1 | 1 | 1997 | 50 | 0.010 |
Why?
|
HeLa Cells | 1 | 1999 | 828 | 0.010 |
Why?
|
Carrier Proteins | 1 | 2002 | 1066 | 0.010 |
Why?
|
Genes, ras | 1 | 1997 | 102 | 0.010 |
Why?
|
Neoplasm Staging | 1 | 2001 | 1384 | 0.010 |
Why?
|
Drug Resistance, Neoplasm | 1 | 2001 | 819 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2001 | 2294 | 0.010 |
Why?
|
Lung | 1 | 2003 | 1557 | 0.010 |
Why?
|
Transcriptional Activation | 1 | 1997 | 497 | 0.010 |
Why?
|
Adenocarcinoma | 1 | 2001 | 1070 | 0.010 |
Why?
|